Description of Invention: This technology describes improved methods of synthesis for conjugate vaccines, specifically those against anthrax. The inventors' method is designed to synthesize immunogenic conjugates (i.e., a protein carrier conjugated to a bacterially derived synthetic peptide) that are prepared at a physiological pH, not reversible and do not require reduction with borohydride. The inventors' method comprises reacting the protein carrier with a dihydrazide, and the peptide with a benzaldehyde, or the reverse, then reacting the derivatized peptide and the derivatized protein with each other to form an immunogenic conjugate.
Applications: Methods for making conjugate vaccines and reagents.
Advantages: More efficient conjugation methods, higher conjugate yields.
Development Status: Vaccine candidates have been synthesized and preclinical studies have been performed.
Inventors: Rachel Schneerson (NICHD) Joanna Kubler-kielb (NICHD) Fathy D Majadly (NICHD) Stephen H Leppla (NIAID) John B Robbins (NICHD) Darrell T Liu (NICHD) Joseph Shiloach (NIDDK)
For Additional Information Please Contact: Peter Soukas J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 14, Rockville, MD 20852-3804 United States Email: soukasp@mail.nih.gov Phone: 301-435-4646 Fax: 301-402-0220
Description of Invention:
This technology describes improved methods of synthesis for conjugate vaccines, specifically those against anthrax. The inventors' method is designed to synthesize immunogenic conjugates (i.e., a protein carrier conjugated to a bacterially derived synthetic peptide) that are prepared at a physiological pH, not reversible and do not require reduction with borohydride. The inventors' method comprises reacting the protein carrier with a dihydrazide, and the peptide with a benzaldehyde, or the reverse, then reacting the derivatized peptide and the derivatized protein with each other to form an immunogenic conjugate.
Applications:
Methods for making conjugate vaccines and reagents.
Advantages:
More efficient conjugation methods, higher conjugate yields.
Development Status:
Vaccine candidates have been synthesized and preclinical studies have been performed.
Inventors:
Rachel Schneerson (NICHD)
Joanna Kubler-kielb (NICHD)
Fathy D Majadly (NICHD)
Stephen H Leppla (NIAID)
John B Robbins (NICHD)
Darrell T Liu (NICHD)
Joseph Shiloach (NIDDK)
Patent Status:
HHS, Reference No. E-040-2005/0
US, , Patent No. 7,625,736, Issued 01 Dec 2009
US, Application No. 12/582,420 filed 20 Oct 2009
International rights available
Relevant Publication:
Licensing Status:
Available for licensing.
Portfolios:
Infectious Diseases
Infectious Diseases - Vaccines
Infectious Diseases - Research Materials
For Additional Information Please Contact:
Peter Soukas J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 14,
Rockville, MD 20852-3804
United States
Email: soukasp@mail.nih.gov
Phone: 301-435-4646
Fax: 301-402-0220
Ref No: 1970
Updated: 06/2009